This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
chronic obstructive | 1713 |
pulmonary disease | 1657 |
obstructive pulmonary | 1619 |
copd patients | 931 |
epithelial cells | 703 |
lung function | 633 |
intensive care | 545 |
lung cancer | 526 |
lung disease | 506 |
copd exacerbations | 431 |
acute exacerbations | 428 |
signifi cant | 404 |
respiratory failure | 391 |
mechanical ventilation | 378 |
respiratory tract | 375 |
mean age | 363 |
signifi cantly | 361 |
cigarette smoke | 353 |
identifi ed | 347 |
airway inflammation | 339 |
emergency department | 333 |
acute respiratory | 331 |
risk factors | 326 |
viral infections | 308 |
chronic bronchitis | 307 |
airway epithelial | 301 |
care unit | 283 |
infl ammation | 269 |
infl ammatory | 264 |
health care | 257 |
oxidative stress | 256 |
cystic fibrosis | 255 |
acute exacerbation | 253 |
confl ict | 253 |
viral infection | 243 |
ethics regulations | 238 |
respiratory viruses | 230 |
gene expression | 225 |
lung diseases | 225 |
immune response | 224 |
septic shock | 222 |
patients admitted | 217 |
control group | 215 |
two groups | 208 |
pulmonary function | 205 |
infl uenza | 204 |
pulmonary fibrosis | 202 |
critically ill | 201 |
alveolar macrophages | 201 |
rhinovirus infection | 199 |
pulmonary rehabilitation | 194 |
respiratory symptoms | 192 |
respiratory disease | 191 |
smooth muscle | 188 |
increased risk | 187 |
cohort study | 178 |
controlled trial | 174 |
statistically significant | 172 |
rv infection | 170 |
lung tissue | 170 |
inflammatory response | 170 |
respiratory syncytial | 170 |
lower respiratory | 169 |
immune responses | 169 |
primary care | 168 |
severe asthma | 166 |
asthma exacerbations | 166 |
blood pressure | 164 |
logistic regression | 164 |
systematic review | 164 |
syncytial virus | 164 |
bronchial epithelial | 161 |
cardiac arrest | 159 |
innate immune | 159 |
copd exacerbation | 158 |
fi rst | 157 |
risk factor | 152 |
randomized controlled | 150 |
ill patients | 150 |
healthy controls | 149 |
heart failure | 149 |
fi brosis | 148 |
lung injury | 148 |
bacterial infection | 147 |
haemophilus influenzae | 145 |
severe copd | 144 |
respiratory distress | 144 |
bronchoalveolar lavage | 143 |
study period | 141 |
determine whether | 141 |
clinical trials | 141 |
significantly higher | 140 |
measured using | 137 |
significant difference | 137 |
defi ned | 135 |
human lung | 135 |
air pollution | 135 |
heart rate | 134 |
mg kg | 134 |
may also | 134 |
antibiotic therapy | 134 |
growth factor | 133 |
important role | 133 |
median age | 132 |
asthmatic patients | 132 |
fl uid | 131 |
obstructive lung | 131 |
stable copd | 130 |
adult patients | 130 |
dendritic cells | 130 |
pulmonary hypertension | 129 |
nitric oxide | 128 |
virus infection | 128 |
prospective study | 126 |
mortality rate | 126 |
doc id | 125 |
cord uid | 125 |
chronic respiratory | 124 |
invasive ventilation | 124 |
peripheral blood | 124 |
hospital mortality | 123 |
icu admission | 122 |
immune system | 122 |
asthma control | 122 |
apoptotic cells | 121 |
fev fvc | 121 |
airflow limitation | 120 |
chronic lung | 119 |
respiratory viral | 119 |
significant differences | 118 |
copd subjects | 117 |
respiratory infections | 117 |
inhaled corticosteroids | 117 |
age years | 117 |
airflow obstruction | 116 |
airway epithelium | 116 |
carbon monoxide | 116 |
blood flow | 115 |
month period | 113 |
patients presenting | 111 |
years old | 111 |
ng ml | 110 |
among patients | 110 |
elderly patients | 109 |
mm hg | 108 |
fi ndings | 108 |
interstitial lung | 108 |
clinical practice | 108 |
epithelial cell | 108 |
one patient | 107 |
side effects | 107 |
hospital admission | 106 |
data suggest | 106 |
pseudomonas aeruginosa | 106 |
acquired pneumonia | 106 |
pulmonary artery | 105 |
observational study | 104 |
idiopathic pulmonary | 103 |
mrna expression | 103 |
inflammatory cells | 102 |
high risk | 102 |
disease severity | 102 |
arterial blood | 101 |
respiratory diseases | 101 |
physical activity | 100 |
tract infections | 100 |
airway obstruction | 99 |
organ failure | 99 |
ed patients | 99 |
factors associated | 99 |
airway smooth | 98 |
performed using | 98 |
respiratory system | 98 |
primary outcome | 98 |
icu patients | 97 |
multivariate analysis | 97 |
cardiac output | 97 |
pulmonary embolism | 97 |
patients received | 96 |
united states | 96 |
smoking cessation | 96 |
inflammatory cytokines | 96 |
severe acute | 95 |
asthmatic subjects | 95 |
gas exchange | 95 |
leading cause | 95 |
chest pain | 94 |
patients treated | 94 |
young children | 94 |
upper respiratory | 94 |
fev predicted | 93 |
consecutive patients | 93 |
bacterial infections | 93 |
pg ml | 92 |
tidal volume | 92 |
acute lung | 91 |
respiratory rate | 90 |
least one | 90 |
animal models | 90 |
airways disease | 90 |
retrospective study | 90 |
goblet cell | 89 |
heme oxygenase | 89 |
severe exacerbations | 89 |
group i | 88 |
ed visits | 88 |
mesenchymal stem | 88 |
ml kg | 88 |
upper airway | 87 |
inclusion criteria | 87 |
distress syndrome | 87 |
lower airway | 87 |
human rhinovirus | 86 |
bone marrow | 86 |
statistical analysis | 86 |
vocal cord | 86 |
oxygen saturation | 86 |
induced sputum | 86 |
apoptotic cell | 85 |
pilot study | 85 |
significantly lower | 85 |
healthy subjects | 85 |
increased airway | 84 |
adverse events | 84 |
adverse effects | 84 |
patients without | 84 |
mouse model | 84 |
cell lines | 83 |
lung transplant | 83 |
stem cells | 83 |
commonly used | 83 |
respiratory illness | 83 |
older adults | 83 |
action plan | 82 |
experimental rhinovirus | 82 |
oxygen therapy | 82 |
three patients | 82 |
apache ii | 81 |
hospital admissions | 81 |
airway pressure | 81 |
lung volume | 81 |
cystic fi | 81 |
long term | 81 |
mechanically ventilated | 81 |
influenza virus | 81 |
emergency medicine | 81 |
necrosis factor | 80 |
critical care | 80 |
lung inflammation | 80 |
interest nil | 80 |
cant differences | 80 |
myocardial infarction | 80 |
asm cells | 80 |
interest none | 80 |
odds ratio | 79 |
control subjects | 79 |
clinical trial | 79 |
year period | 79 |
mouse models | 79 |
inflammatory responses | 78 |
university hospital | 78 |
current smokers | 78 |
immune cells | 78 |
two patients | 78 |
inflammatory mediators | 77 |
hospital stay | 77 |
controlled trials | 77 |
asm cell | 77 |
results patients | 77 |
air travel | 77 |
human airway | 76 |
present study | 76 |
lower airways | 76 |
acute bronchitis | 76 |
regression analysis | 75 |
cantly higher | 75 |
author funder | 75 |
granted medrxiv | 75 |
independently associated | 74 |
significant increase | 74 |
respiratory virus | 74 |
medical records | 74 |
clinical characteristics | 74 |
blood gas | 74 |
stem cell | 73 |
airway disease | 73 |
increased expression | 73 |
sputum samples | 73 |
patients hospitalized | 73 |
coronavirus disease | 73 |
extracellular matrix | 73 |
smoking history | 72 |
significantly increased | 72 |
airway narrowing | 72 |
cytokine production | 72 |
public health | 72 |
respiratory syndrome | 71 |
renal failure | 71 |
stable patients | 71 |
mass index | 71 |
informed consent | 71 |
predictive value | 71 |
like receptor | 70 |
pulmonary vascular | 70 |
copyright holder | 69 |
year old | 69 |
care providers | 69 |
recent studies | 69 |
general population | 69 |
hypercapnic respiratory | 69 |
patients receiving | 69 |
significantly reduced | 69 |
world health | 69 |
infl uence | 69 |
tobacco smoke | 68 |
forced expiratory | 68 |
lung transplantation | 68 |
made available | 68 |
body mass | 68 |
previous studies | 68 |
may contribute | 68 |
trauma patients | 68 |
clinical data | 68 |
inflammatory markers | 68 |
viral replication | 68 |
current asthma | 67 |
antibiotic treatment | 67 |
polymerase chain | 67 |
chain reaction | 67 |
cigarette smoking | 67 |
icu stay | 67 |
hypertonic saline | 67 |
arterial pressure | 67 |
care units | 67 |
streptococcus pneumoniae | 67 |
ventilated patients | 66 |
within hours | 66 |
pao fio | 66 |
acute asthma | 66 |
airfl ow | 66 |
heart disease | 66 |
age groups | 66 |
tumor necrosis | 66 |
ct scan | 65 |
global initiative | 65 |
lung microbiome | 65 |
disease progression | 65 |
airway hyperresponsiveness | 65 |
barrier function | 65 |
thoracic society | 65 |
small airways | 65 |
cord movement | 64 |
blood gases | 64 |
tertiary care | 64 |
clinical outcomes | 64 |
adaptive immune | 64 |
admission rates | 64 |
included patients | 64 |
time spent | 63 |
ow obstruction | 63 |
pulmonary diseases | 63 |
sectional study | 63 |
chronic inflammatory | 63 |
airway macrophages | 63 |
significantly associated | 63 |
molecular mechanisms | 62 |
international license | 62 |
hospitalized patients | 62 |
sample size | 62 |
results suggest | 62 |
ml min | 62 |
statistically signifi | 62 |
clinical features | 62 |
respiratory infection | 62 |
patients undergoing | 61 |
increased levels | 61 |
expiratory flow | 61 |
cell surface | 61 |
may play | 61 |
induced lung | 61 |
systemic inflammation | 61 |
type i | 61 |
significantly different | 61 |
function tests | 61 |
health status | 61 |
mean difference | 61 |
cell proliferation | 60 |
nontypeable haemophilus | 60 |
airway infl | 60 |
asthma symptoms | 60 |
linear regression | 60 |
analysed using | 60 |
expiratory volume | 60 |
health organization | 60 |
version posted | 60 |
cellular senescence | 60 |
carbon dioxide | 60 |
central venous | 60 |
study aimed | 59 |
obstructive sleep | 59 |
smoke exposure | 59 |
blood cultures | 59 |
pleural ultrasound | 59 |
nomination nil | 59 |
group ii | 59 |
patients died | 58 |
ammatory cytokines | 58 |
pressure support | 58 |
tidal breathing | 58 |
asthma exacerbation | 58 |
healthy volunteers | 58 |
several studies | 58 |
chronic cough | 58 |
high levels | 58 |
data collection | 58 |
asthma patients | 57 |
cant difference | 57 |
cancer cells | 57 |
gas transfer | 57 |
sex hormones | 57 |
within days | 57 |
airway diseases | 57 |
acute care | 57 |
well tolerated | 57 |
adhesion molecule | 57 |
cell death | 57 |
mean fev | 57 |
function testing | 57 |
confi rmed | 56 |
lung volumes | 56 |
proinflammatory cytokines | 56 |
neutrophil elastase | 56 |
stable state | 56 |
sputum production | 56 |
noninvasive ventilation | 56 |
asm layer | 56 |
induced exacerbations | 56 |
reactive protein | 56 |
crp levels | 56 |
neutrophilic inflammation | 56 |
median time | 56 |
patients may | 55 |
peak flow | 55 |
childhood asthma | 55 |
cell types | 55 |
nucleic acid | 55 |
persistent asthma | 55 |
retrospective review | 55 |
pleural effusions | 55 |
chronic diseases | 55 |
prospective observational | 55 |
vital signs | 54 |
data collected | 54 |
differentially expressed | 54 |
gold stage | 54 |
protein levels | 54 |
tissue damage | 54 |
exacerbation frequency | 54 |
diffi cult | 54 |
odds ratios | 54 |
international congresses | 54 |
bacterial colonization | 54 |
mycobacterium tuberculosis | 54 |
gold standard | 54 |
exercise capacity | 53 |
global strategy | 53 |
treatment failure | 53 |
secondary outcomes | 53 |
prospective cohort | 53 |
reactive oxygen | 53 |
oxygen species | 53 |
mean value | 53 |
ab ab | 53 |
support nhmrc | 52 |
current study | 52 |
gene transfer | 52 |
culture positive | 52 |
significant improvement | 52 |
study population | 52 |
cardiac surgery | 52 |
induced pulmonary | 52 |
minute walk | 52 |
per year | 52 |
smoking status | 52 |
chest wall | 52 |
virus infections | 52 |
mental health | 52 |
ventilatory support | 52 |
replacement therapy | 52 |
computed tomography | 52 |
time pcr | 52 |
children aged | 52 |
effi cacy | 52 |
control study | 52 |
respiratory health | 51 |
host immune | 51 |
may lead | 51 |
induced asthma | 51 |
analyzed using | 51 |
allergic asthma | 51 |
endothelial cells | 51 |
allergic airway | 51 |
goblet cells | 51 |
ii score | 51 |
spent outdoors | 51 |
palliative care | 51 |
fl ow | 51 |
average age | 50 |
days post | 50 |
mucus production | 50 |
may result | 50 |
age group | 50 |
study group | 50 |
bronchial epithelium | 50 |
seven patients | 50 |
recent study | 50 |
descriptive statistics | 50 |
particulate matter | 50 |
flow cytometry | 50 |
transcription factor | 50 |
receptor expression | 49 |
innate immunity | 49 |
chronic disease | 49 |
time points | 49 |
respiratory function | 49 |
one study | 49 |
airway resistance | 49 |
assessed using | 49 |
peak expiratory | 49 |
may reduce | 49 |
disease exacerbations | 49 |
clinically relevant | 49 |
pulmonary arterial | 49 |
transforming growth | 49 |
methods subjects | 49 |
saps ii | 48 |
protein expression | 48 |
pleural fl | 48 |
frequent exacerbations | 48 |
sofa score | 48 |
nucleic acids | 48 |
converting enzyme | 48 |
new zealand | 48 |
one year | 48 |
severe sepsis | 48 |
ed visit | 48 |
survival rate | 48 |
health study | 48 |
randomised controlled | 48 |
diffusing capacity | 48 |
airway responsiveness | 48 |
clinically significant | 48 |
common cause | 48 |
chart review | 48 |
right ventricular | 48 |
inhaler technique | 47 |
influenza vaccination | 47 |
success rate | 47 |
serum levels | 47 |
human disease | 47 |
total lung | 47 |
ventilation heterogeneity | 47 |
pleural effusion | 47 |
minute ventilation | 47 |
protein kinase | 47 |
mucus hypersecretion | 47 |
alveolar macrophage | 47 |
energy expenditure | 47 |
mean duration | 47 |
lung epithelial | 46 |
epithelial barrier | 46 |
oral corticosteroids | 46 |
tract infection | 46 |
infectious diseases | 46 |
blood samples | 46 |
human metapneumovirus | 46 |
adhesion molecules | 46 |
oscillation technique | 46 |
medrxiv preprint | 46 |
case report | 46 |
adverse event | 46 |
airway wall | 46 |
skeletal muscle | 46 |
cell line | 46 |
also found | 45 |
forced oscillation | 45 |
congestive heart | 45 |
nutritional status | 45 |
expression levels | 45 |
brain injury | 45 |
mucociliary clearance | 45 |
medical care | 45 |
dynamic hyperinflation | 45 |
blended learning | 45 |
exclusion criteria | 45 |
aged years | 45 |
acute rejection | 45 |
increased susceptibility | 45 |
diabetes mellitus | 45 |
determined using | 45 |
may provide | 45 |
studies using | 45 |
kg min | 45 |
chronic inflammation | 45 |
methods patients | 44 |
vascular resistance | 44 |
complication rate | 44 |
muscle cells | 44 |
cell lung | 44 |
allergic rhinitis | 44 |
type ii | 44 |
severe covid | 44 |
high mortality | 44 |
mesenchymal stromal | 44 |
cardiovascular disease | 44 |
dl co | 44 |
focus groups | 44 |
mononuclear cells | 44 |
higher risk | 44 |
lung health | 44 |
vo peak | 44 |
per patient | 44 |
may help | 44 |
inflammatory lung | 44 |
roundtable group | 43 |
major cause | 43 |
peer review | 43 |
early life | 43 |
sex differences | 43 |
significant decrease | 43 |
preliminary results | 43 |
host defense | 43 |
studies suggest | 43 |
moraxella catarrhalis | 43 |
transcription factors | 43 |
mg ml | 43 |
findings suggest | 43 |
one hundred | 43 |
patients diagnosed | 43 |
hyperinfl ation | 43 |
stable chronic | 43 |
invasive mechanical | 43 |
study aims | 42 |
hh pathway | 42 |
foreign body | 42 |
gord symptoms | 42 |
intervention group | 42 |
airway distensibility | 42 |
pressure ventilation | 42 |
cancer patients | 42 |
airway remodelling | 42 |
type diabetes | 42 |
vte prophylaxis | 42 |
ow cytometry | 42 |
patient demographics | 42 |
disease control | 42 |
asthma severity | 42 |
gold guidelines | 41 |
symptom scores | 41 |
cytokine release | 41 |
clinical course | 41 |
airway remodeling | 41 |
medication use | 41 |
demographic data | 41 |
pulmonary inflammation | 41 |
body weight | 41 |
older people | 41 |
inflammatory cytokine | 41 |
multiple organ | 41 |
respiratory pathogens | 41 |
exhaled nitric | 41 |
weight loss | 41 |
low risk | 41 |
patients requiring | 40 |
increased sputum | 40 |
western blot | 40 |
future studies | 40 |
fi broblasts | 40 |
three different | 40 |
methods retrospective | 40 |
diagnostic yield | 40 |
overall survival | 40 |
patient care | 40 |
increased mortality | 40 |
novel coronavirus | 40 |
septic patients | 40 |
copd may | 40 |
patients aged | 40 |
see table | 40 |
elastic recoil | 40 |
endotracheal tube | 40 |
medical center | 40 |
univariate analysis | 40 |
copd group | 39 |
four patients | 39 |
patients showed | 39 |
three months | 39 |
walk test | 39 |
community acquired | 39 |
environmental factors | 39 |
northern territory | 39 |
matrix metalloproteinase | 39 |
per day | 39 |
emergency departments | 39 |
left ventricular | 39 |
normal subjects | 39 |
osa patients | 39 |
positive airway | 39 |
two years | 39 |
lung tissues | 39 |
respiratory medicine | 39 |
head injury | 39 |
viral respiratory | 39 |
fi ciency | 39 |
months later | 39 |
asthma foundation | 39 |
pulmonary infection | 39 |
house dust | 39 |
immunocompromised patients | 38 |
infection may | 38 |
retrospective cohort | 38 |
higher levels | 38 |
strongly associated | 38 |
also showed | 38 |
stromal cells | 38 |
small airway | 38 |
asthma phenotypes | 38 |
severe persistent | 38 |
quantifi ed | 38 |
patients required | 38 |
positive pressure | 38 |
many patients | 38 |
refl ux | 38 |
mean arterial | 38 |
diagnosed asthma | 38 |
liver disease | 38 |
fi nal | 38 |
compared using | 37 |
methods data | 37 |
severe disease | 37 |
mortality rates | 37 |
study using | 37 |
reproductive factors | 37 |
study showed | 37 |
sleep apnea | 37 |
standard deviation | 37 |
effi ciency | 37 |
vital capacity | 37 |
fold increase | 37 |
increased numbers | 37 |
severe ards | 37 |
fl exible | 37 |
never smokers | 37 |
cell volume | 37 |
lactate levels | 37 |
clinical signs | 37 |
pulmonary edema | 37 |
hospital discharge | 37 |
th cells | 37 |
dust mite | 37 |
also associated | 37 |
acute severe | 37 |
interstitial pneumonia | 37 |
significant reduction | 36 |
mast cells | 36 |
ea bpco | 36 |
medical students | 36 |
respiratory acidosis | 36 |
combination therapy | 36 |
natural history | 36 |
general practice | 36 |
common cold | 36 |
ceacam expression | 36 |
may occur | 36 |
young copd | 36 |
influenza infection | 36 |
neutrophilic asthma | 36 |
cardiac index | 36 |
spontaneous breathing | 36 |
eight patients | 36 |
chlamydia pneumoniae | 36 |
high prevalence | 36 |
viral pathogens | 36 |
collagen iv | 36 |
signaling pathways | 36 |
ammatory mediators | 36 |
allergen exposure | 36 |
data analysis | 36 |
drug delivery | 36 |
macrophage function | 36 |
small number | 36 |
usual care | 36 |
clinical assessment | 36 |
infi ltrates | 36 |
negative predictive | 36 |
written action | 36 |
coronary artery | 36 |
months post | 36 |
limited data | 36 |
mice exposed | 36 |
table shows | 36 |
action plans | 36 |
higher rates | 36 |
medical research | 35 |
plasma levels | 35 |
mg dl | 35 |
pain management | 35 |
growth factors | 35 |
regression model | 35 |
first hours | 35 |
allergic disease | 35 |
early detection | 35 |
key role | 35 |
fvc ratio | 35 |
wide range | 35 |
copd roundtable | 35 |
fl ocked | 35 |
clinically signifi | 35 |
emphysema extent | 35 |
pregnant women | 35 |
initial phase | 35 |
expression profi | 35 |
staphylococcus aureus | 35 |
five patients | 35 |
febrile neutropenia | 35 |
chest radiograph | 35 |
level i | 35 |
cell type | 35 |
arterial hypertension | 35 |
secondary bacterial | 35 |
less likely | 35 |
pulmonary tuberculosis | 35 |
acute renal | 35 |
ten patients | 35 |
pacific region | 35 |
cell culture | 35 |
airway epithelia | 34 |
response rate | 34 |
inhaled corticosteroid | 34 |
statistical difference | 34 |
care services | 34 |
risk patients | 34 |
recent years | 34 |
protective effect | 34 |
spontaneous pneumothorax | 34 |
medical history | 34 |
murine model | 34 |
retrospective audit | 34 |
first days | 34 |
emergency physicians | 34 |
patient outcomes | 34 |
focus group | 34 |
patients compared | 34 |
whole blood | 34 |
without copd | 34 |
retrospective analysis | 34 |
increasing age | 34 |
blood mononuclear | 34 |
study included | 34 |
another study | 34 |
phase iii | 33 |
old male | 33 |
right heart | 33 |
phagocytic ability | 33 |
daily living | 33 |
angiotensin ii | 33 |
antibiotic use | 33 |
last years | 33 |
health outcomes | 33 |
prince charles | 33 |
acute phase | 33 |
inhaled therapy | 33 |
viral load | 33 |
clinical symptoms | 33 |
alveolar epithelial | 33 |
hong kong | 33 |
preliminary data | 33 |
without asthma | 33 |
bone mineral | 33 |
eosinophilic asthma | 33 |
large number | 33 |
syndrome coronavirus | 33 |
study conducted | 33 |
cardiogenic shock | 33 |
ed physicians | 33 |
sleep apnoea | 33 |
reverse transcribed | 33 |
educational intervention | 33 |
acute myocardial | 33 |
human bronchial | 33 |
chest tightness | 33 |
charles hospital | 33 |
acute cough | 33 |
hydrogen peroxide | 33 |
small cell | 33 |
rsv infection | 32 |
patients attending | 32 |
city hospital | 32 |
patients presented | 32 |
ats ers | 32 |
endotracheal intubation | 32 |
confidence interval | 32 |
pediatric patients | 32 |
venous blood | 32 |
even though | 32 |
systemic corticosteroids | 32 |
case series | 32 |
death worldwide | 32 |
control groups | 32 |
poorly understood | 32 |
first year | 32 |
family members | 32 |
lung mechanics | 32 |
overall mortality | 32 |
nuclear factor | 32 |
epidermal growth | 32 |
lung infl | 32 |
bacterial pathogens | 32 |
pulmonary tb | 32 |
oral prednisolone | 32 |
disease exacerbation | 32 |
trend towards | 32 |
clinical outcome | 32 |
six patients | 32 |
bp deletion | 32 |
remains controversial | 32 |
respiratory physicians | 32 |
day mortality | 32 |
recognition receptors | 32 |
demographic characteristics | 32 |
total number | 32 |
previously shown | 32 |
asthma education | 32 |
inflammatory diseases | 31 |
confidence intervals | 31 |
last months | 31 |
antimicrobial peptides | 31 |
fi bre | 31 |
fio ratio | 31 |
cancer cell | 31 |
significant correlation | 31 |
observational cohort | 31 |
bronchopulmonary dysplasia | 31 |
induced airway | 31 |
infl uenzae | 31 |
study shows | 31 |
patients suffering | 31 |
modifi ed | 31 |
secondary analysis | 31 |
experimental infection | 31 |
index case | 31 |
research support | 31 |
taken together | 31 |
ex vivo | 31 |
scientific studies | 31 |
care settings | 31 |
blood culture | 31 |
two methods | 31 |
million people | 31 |
like receptors | 31 |
clinical decision | 31 |
support scientific | 31 |
diagnostic accuracy | 31 |
airway dysfunction | 31 |
may cause | 31 |
teaching hospital | 31 |
widely used | 31 |
viral rna | 31 |
cell counts | 31 |
mechanisms underlying | 31 |
macrophage phagocytosis | 31 |
infection control | 31 |
ammatory response | 30 |
normal range | 30 |
lavage fluid | 30 |
predicted fev | 30 |
decision making | 30 |
related quality | 30 |
care bundle | 30 |
asthma management | 30 |
independent risk | 30 |
poor prognosis | 30 |
flow rate | 30 |
airway hyper | 30 |
lung parenchyma | 30 |
lung cancers | 30 |
calculated using | 30 |
respiratory mechanics | 30 |
tight junctions | 30 |
time course | 30 |
convenience sample | 30 |
infected cells | 30 |
exercise tolerance | 30 |
icu mortality | 30 |
muc ac | 30 |
symptom control | 30 |
ed using | 30 |
exact test | 30 |
disease patients | 30 |
lung capacity | 30 |
protective role | 30 |
signaling pathway | 30 |
bacterial load | 30 |
national health | 30 |
healthy individuals | 30 |
mean values | 30 |
one subject | 30 |
immune defect | 30 |
renal replacement | 30 |
well established | 30 |
treatment options | 30 |
general medical | 30 |
high fat | 30 |
diesel exhaust | 29 |
also assessed | 29 |
significantly improved | 29 |
children born | 29 |
pleural infection | 29 |
connective tissue | 29 |
bronchial asthma | 29 |
cell hyperplasia | 29 |
patient groups | 29 |
allergen challenge | 29 |
airway cells | 29 |
exible bronchoscopy | 29 |
acting beta | 29 |
quantifi cation | 29 |
ct scans | 29 |
therapeutic intervention | 29 |
inhaled steroids | 29 |
lymph nodes | 29 |
two different | 29 |
diagnostic tests | 29 |
antitrypsin deficiency | 29 |
trauma center | 29 |
eosinophilic inflammation | 29 |
hfnc group | 29 |
lymph node | 29 |
prognostic factors | 29 |
cell apoptosis | 29 |
transplant patients | 29 |
disordered breathing | 29 |
reduced expression | 29 |
conducting airways | 29 |
oxygen consumption | 29 |
infected mice | 29 |
activated protein | 29 |
health services | 29 |
sex ratio | 29 |
outcome measures | 29 |
older age | 29 |
sputum purulence | 29 |
two studies | 29 |
study design | 29 |
surfactant protein | 29 |
infection induces | 29 |
randomized clinical | 29 |
observational studies | 29 |
sprint junior | 28 |
inflammatory cell | 28 |
copd pathogenesis | 28 |
lc sprint | 28 |
cantly different | 28 |
second test | 28 |
ww use | 28 |
emergency room | 28 |
exercise training | 28 |
appropriate vte | 28 |
sputum induction | 28 |
cell parameters | 28 |
patients reported | 28 |
study suggests | 28 |
viral exacerbations | 28 |
ocked swabs | 28 |
advanced glycation | 28 |
body inhalation | 28 |
discharge care | 28 |
classifi ed | 28 |
cell metaplasia | 28 |
using standard | 28 |
requiring mechanical | 28 |
patient population | 28 |
high level | 28 |
retrospective chart | 28 |
intercellular adhesion | 28 |
forced vital | 28 |
quantitative pcr | 28 |
ethics committee | 28 |
clinical studies | 28 |
receiver operating | 28 |
low dose | 28 |
niv group | 28 |
patient age | 28 |
oxygen use | 28 |
null mefs | 28 |
ipf patients | 28 |
pulmonary infi | 28 |
rhinovirus colds | 28 |
metal screws | 28 |
may increase | 28 |
haematological malignancy | 28 |
clinical presentation | 28 |
recurrent exacerbations | 28 |
cell adhesion | 28 |
sleep study | 28 |
ct larynx | 28 |
olic acid | 28 |
acute copd | 28 |
positive predictive | 28 |
pulmonary fi | 28 |
lung fibrosis | 28 |
younger age | 28 |
pacifi ca | 28 |
mitochondrial dysfunction | 28 |
family history | 28 |
nasal fl | 28 |
associated pneumonia | 28 |
without bpd | 28 |
highly prevalent | 28 |
born preterm | 28 |
significantly decreased | 28 |
significant change | 28 |
median length | 27 |
mesenchymal transition | 27 |
lung infection | 27 |
diagnostic procedures | 27 |
function impairment | 27 |
glycation end | 27 |
respiratory questionnaire | 27 |
cell numbers | 27 |
cantly lower | 27 |
respiratory muscle | 27 |
asthma outcomes | 27 |
nhbe cells | 27 |
lung damage | 27 |
american thoracic | 27 |
glasgow coma | 27 |
smoke extract | 27 |
increased inflammation | 27 |
cell migration | 27 |
allergic diseases | 27 |
well known | 27 |
care system | 27 |
preterm birth | 27 |
methods children | 27 |
air quality | 27 |
lung resection | 27 |
cell pro | 27 |
viral pathogen | 27 |
chronic asthma | 27 |
nervous system | 27 |
scoring system | 27 |
thoracic medicine | 27 |
depth image | 27 |
independent predictors | 27 |
patient satisfaction | 27 |
clinical parameters | 27 |
significant changes | 27 |
corticosteroid therapy | 27 |
study will | 27 |
data indicate | 27 |
data will | 27 |
i trauma | 27 |
hours post | 27 |
influenza viruses | 27 |
one hour | 27 |
airways inflammation | 27 |
patient characteristics | 27 |
wt mice | 27 |
service model | 27 |
higher mortality | 27 |
blood lactate | 27 |
organ dysfunction | 26 |
tertiary hospital | 26 |
oxygen desaturation | 26 |
clinical diagnosis | 26 |
per hour | 26 |
disease pathogenesis | 26 |
flow nasal | 26 |
asthma action | 26 |
statistical significance | 26 |
medical record | 26 |
randomly assigned | 26 |
parainfl uenza | 26 |
first study | 26 |
human cell | 26 |
radiation exposure | 26 |
ards patients | 26 |
stage iii | 26 |
traumatic brain | 26 |
national heart | 26 |
poor asthma | 26 |
steroid treatment | 26 |
breath condensate | 26 |
patients underwent | 26 |
randomly selected | 26 |
outcome measure | 26 |
positive correlation | 26 |
collected included | 26 |
significantly less | 26 |
oxygen supplementation | 26 |
liver transplantation | 26 |
pattern recognition | 26 |
chief complaint | 26 |
activity levels | 26 |
better understanding | 26 |
chronic rhinosinusitis | 26 |
benefi ts | 26 |
exhaled breath | 26 |
epidemiological studies | 26 |
niv failure | 26 |
abdominal pain | 26 |
cd cd | 26 |
host response | 26 |
one case | 26 |
time period | 26 |
admitted patients | 26 |
results participants | 26 |
acute viral | 26 |
medical staff | 26 |
early diagnosis | 26 |
volume density | 26 |
niv service | 26 |
high dose | 26 |
air pollutants | 26 |
collected data | 26 |
year follow | 26 |
many studies | 25 |
non invasive | 25 |
carcinoembryonic antigen | 25 |
hemodynamic parameters | 25 |
previously described | 25 |
longitudinal health | 25 |
atrial fibrillation | 25 |
first time | 25 |
asthma development | 25 |
sputum cultures | 25 |
remains unclear | 25 |
education program | 25 |
results show | 25 |
evidence suggests | 25 |
volume fraction | 25 |
surgical intervention | 25 |
real time | 25 |
year survival | 25 |
bronchodilator response | 25 |
tasmanian longitudinal | 25 |
average length | 25 |
patients infected | 25 |
old copd | 25 |
normal lung | 25 |
intubated patients | 25 |
healthy smokers | 25 |
common respiratory | 25 |
pulmonary emphysema | 25 |
inflammatory process | 25 |
respiratory illnesses | 25 |
geometric mean | 25 |
blood volume | 25 |
sea level | 25 |
nine patients | 25 |
associated molecular | 25 |
following treatment | 25 |
asthma pathogenesis | 25 |
inflammatory effects | 25 |
intercostal catheter | 25 |
incidence rate | 25 |
pacientes con | 25 |
may affect | 25 |
artery pressure | 25 |
general practitioners | 25 |
dependent manner | 25 |
tuberculosis infection | 25 |
academic ed | 25 |
severe chronic | 25 |
three groups | 25 |
chronic airway | 25 |
bacterial species | 25 |
wild type | 25 |
therapeutic strategies | 25 |
case reports | 25 |
influenza vaccine | 25 |
patients referred | 25 |
likely due | 25 |
antibiotic resistance | 25 |
liver function | 25 |
venous thrombosis | 25 |
airway neutrophilia | 25 |
fatty acids | 25 |
care contacts | 25 |
following rv | 25 |
experimental rv | 25 |
expiratory pressure | 25 |
decreased expression | 25 |
asthmatic children | 25 |
proinflammatory cytokine | 25 |
sirna delivery | 25 |
el tratamiento | 25 |
disease caused | 25 |
old non | 25 |
common symptom | 25 |
blood institute | 25 |
economic burden | 25 |
kidney injury | 24 |
clinical audit | 24 |
image sensor | 24 |
port hedland | 24 |
alveolar epithelium | 24 |
cell count | 24 |
systolic blood | 24 |
normal spirometry | 24 |
retrospective case | 24 |
young non | 24 |
risk group | 24 |
asthma candidate | 24 |
diagnostic criteria | 24 |
respiratory muscles | 24 |
health problem | 24 |
dietary intake | 24 |
endotoxin levels | 24 |
function decline | 24 |
literature review | 24 |
posted june | 24 |
surface area | 24 |
chronic infl | 24 |
relative risk | 24 |
tissue samples | 24 |
cells may | 24 |
study involving | 24 |
tight junction | 24 |
cardiac function | 24 |
significantly elevated | 24 |
viral titre | 24 |
often used | 24 |
patients following | 24 |
patients using | 24 |
identifi cation | 24 |
increased significantly | 24 |
glucose tolerance | 24 |
natural killer | 24 |
future research | 24 |
profi le | 24 |
systemic inflammatory | 24 |
additional file | 24 |
urgent hcu | 24 |
recent evidence | 24 |
potential therapeutic | 24 |
th day | 24 |
cell clearance | 24 |
royal adelaide | 24 |
central role | 24 |
las agudizaciones | 24 |
induced emphysema | 24 |
poor outcome | 24 |
sleep disordered | 24 |
des arg | 24 |
sputum volume | 24 |
walk distance | 24 |
patients completed | 24 |
normal cxr | 24 |
smokers vs | 24 |
identify patients | 24 |
using pcr | 24 |
antimicrobial therapy | 24 |
four groups | 24 |
respiratory epithelial | 24 |
pediatric emergency | 24 |
human respiratory | 24 |
factor receptor | 24 |
rage expression | 24 |
deficient mice | 24 |
like cells | 24 |
mycoplasma pneumoniae | 24 |
injury severity | 24 |
older patients | 24 |
patients discharged | 24 |
rat model | 24 |
new treatment | 24 |
higher incidence | 24 |
available data | 24 |
mc sn | 24 |
ics laba | 24 |
aspiration pneumonia | 24 |
tyrosine kinase | 24 |
adjusted odds | 24 |
internal medicine | 24 |
primary health | 24 |
severity score | 24 |
bacterial clearance | 24 |
results showed | 24 |
young adults | 24 |
hospital cardiac | 24 |
subjects underwent | 24 |
saline challenge | 23 |
fifty percent | 23 |
investigated whether | 23 |
global burden | 23 |
socioeconomic status | 23 |
gas analysis | 23 |
samples collected | 23 |
jugular bulb | 23 |
airway management | 23 |
th cytokines | 23 |
composite outcome | 23 |
therapeutic approaches | 23 |
least two | 23 |
studies showed | 23 |
fatty acid | 23 |
eosinophil count | 23 |
attending physician | 23 |
acute kidney | 23 |
will provide | 23 |
analysis showed | 23 |
cycle ergometer | 23 |
copd prevalence | 23 |
emergency care | 23 |
wilcoxon signed | 23 |
previously reported | 23 |
positive cases | 23 |
otitis media | 23 |
clinical care | 23 |
transplant recipients | 23 |
diagnostic procedure | 23 |
knockout mice | 23 |
pack years | 23 |
blood cells | 23 |
twice daily | 23 |
selected patients | 23 |
respiratory events | 23 |
severe head | 23 |
asthma medication | 23 |
pneumonia severity | 23 |
mean score | 23 |
chronic airways | 23 |
wound healing | 23 |
ventilation perfusion | 23 |
health system | 23 |
bronchodilator fev | 23 |
randomized trial | 23 |
mean scores | 23 |
greater risk | 23 |
partial pressure | 23 |
virus replication | 23 |
molecular weight | 23 |
vitro studies | 23 |
gradient centrifugation | 23 |
oxygen delivery | 23 |
asthma copd | 23 |
venous pressure | 23 |
previous year | 23 |
tidal volumes | 23 |
typeable haemophilus | 23 |
total protein | 23 |
lung biopsy | 23 |
mannose receptor | 23 |
severe respiratory | 23 |
interquartile range | 23 |
therapeutic target | 23 |
significantly greater | 23 |
eligible patients | 23 |
positively correlated | 23 |
primary endpoint | 23 |
ace mrna | 23 |
adelaide hospital | 23 |
human subjects | 23 |
guidelines recommend | 23 |
major risk | 23 |
cell function | 23 |
remain unclear | 23 |
cant increase | 23 |
phase ii | 23 |
infl uenced | 23 |
type iii | 22 |
will allow | 22 |
recent data | 22 |
baseline airway | 22 |
three major | 22 |
airway bacterial | 22 |
will inform | 22 |
muscle weakness | 22 |
three age | 22 |
cant correlation | 22 |
artery catheter | 22 |
foreign bodies | 22 |
androgen receptor | 22 |
ejection fraction | 22 |
immune cell | 22 |
standard exercise | 22 |
physical examination | 22 |
new method | 22 |
molecular patterns | 22 |
national surveillance | 22 |
one week | 22 |
rheumatoid arthritis | 22 |
en pacientes | 22 |
heart surgery | 22 |
also shown | 22 |
cantly less | 22 |
induced inflammation | 22 |
positive results | 22 |
lpc lv | 22 |
nthi infection | 22 |
year mortality | 22 |
adaptive immunity | 22 |
airways obstruction | 22 |
cytokine response | 22 |
critical role | 22 |
three hospitals | 22 |
may represent | 22 |
previous months | 22 |
mechanisms may | 22 |
drug use | 22 |
face mask | 22 |
bacterial pneumonia | 22 |
malignant mesothelioma | 22 |
lower levels | 22 |
infected patients | 22 |
diaphragm dysfunction | 22 |
stromal cell | 22 |
primary composite | 22 |
target genes | 22 |
stimulating factor | 22 |
neutrophil recruitment | 22 |
incidence rates | 22 |
positive result | 22 |
ultrasound training | 22 |
using multiparameter | 22 |
pulmonary gas | 22 |
airway lumen | 22 |
female sex | 22 |
postoperative period | 22 |
pulmonary blood | 22 |
positive blood | 22 |
disease requiring | 22 |
image guidance | 22 |
factors including | 22 |
venous access | 22 |
repeated measures | 22 |
defi ne | 22 |
animal model | 22 |
unknown whether | 22 |
former smokers | 22 |
adenoviral infection | 22 |
plus bal | 22 |
median number | 22 |
standard care | 22 |
home niv | 22 |
predictive factors | 22 |
support ventilation | 22 |
acute physiology | 22 |
copd discharge | 22 |
mrc grade | 22 |
surface receptor | 22 |
mixed venous | 22 |
ep receptors | 22 |
bl mice | 22 |
mouse trachea | 22 |
bronchial lavage | 22 |
transmural pressure | 22 |
increasing number | 22 |
emergency medical | 22 |
nk cells | 22 |
systemic glucocorticoids | 22 |
primary human | 22 |
term exposure | 22 |
smokers group | 22 |
asthma attacks | 22 |
also increased | 22 |
health conditions | 22 |
signalling pathways | 22 |
nasal washes | 22 |
potentially life | 22 |
high morbidity | 22 |
grant support | 22 |
transcript levels | 22 |
neutrophilic infl | 21 |
capsule endoscope | 21 |
third leading | 21 |
mortality associated | 21 |
core competencies | 21 |
studies will | 21 |
step pcr | 21 |
clinical setting | 21 |
bed days | 21 |
proportion immune | 21 |
much higher | 21 |
risk interventions | 21 |
reduced lung | 21 |
remains unknown | 21 |
pathway genes | 21 |
positive test | 21 |
elevated rvsp | 21 |
lower fi | 21 |
positive control | 21 |
asthmatic airway | 21 |
tobacco smoking | 21 |
mucous cells | 21 |
superoxide dismutase | 21 |
assess whether | 21 |
also play | 21 |
reduced dlco | 21 |
test results | 21 |
extended family | 21 |
nan title | 21 |
bore icc | 21 |
renal function | 21 |
statistical analyses | 21 |
international recommendations | 21 |
early phase | 21 |
sputum culture | 21 |
colistin use | 21 |
developing countries | 21 |
following stimulation | 21 |
total adr | 21 |
based therapy | 21 |
ventilation distribution | 21 |
prospective studies | 21 |
adl score | 21 |
rank test | 21 |
clinic population | 21 |
cough rate | 21 |
coma scale | 21 |
citrate increased | 21 |
native lung | 21 |
important cause | 21 |
take charge | 21 |
per group | 21 |
rhinovirus infections | 21 |
neutrophilic aad | 21 |
children recruited | 21 |
prone position | 21 |
eflow rapid | 21 |
key hh | 21 |
aeroneb go | 21 |
bronchoscopy plus | 21 |
relieves dyspnoea | 21 |
caudal lobe | 21 |
cpap implementation | 21 |
tj proteins | 21 |
blood transfusion | 21 |
may suggest | 21 |
mw achieved | 21 |
clinical management | 21 |
baseline characteristics | 21 |
dendritic cell | 21 |
transplant rejection | 21 |
higher percentage | 21 |
tertiary referral | 21 |
nebulization time | 21 |
lung cells | 21 |
th responses | 21 |
underlying mechanisms | 21 |
dietary intakes | 21 |
positive upa | 21 |
stage ii | 21 |
requiring hospitalization | 21 |
participants underwent | 21 |
ep receptor | 21 |
clinical research | 21 |
day post | 21 |
muscle strength | 21 |
following admission | 21 |
fi lter | 21 |
hrv detection | 21 |
aboriginal children | 21 |
neutrophil proteases | 21 |
rst exposure | 21 |
health effects | 21 |
candidate genes | 21 |
mucus secretion | 21 |
patients developed | 21 |
broad spectrum | 21 |
phase i | 21 |
pulmonary side | 21 |
medical wards | 21 |
healthy population | 21 |
volume fractions | 21 |
cold symptoms | 21 |
tc groups | 21 |
prehospital setting | 21 |
medical conditions | 21 |
histone deacetylase | 21 |
ammatory phenotypes | 21 |
blot analysis | 21 |
ultrasound marking | 21 |
noninvasive positive | 21 |
received lpc | 21 |
implementation sleep | 21 |
translation effi | 21 |
induced il | 21 |
natriuretic peptide | 21 |
respiratory conditions | 21 |
animal studies | 21 |
disease management | 21 |
productive cough | 21 |
breathing pattern | 21 |
niv relieves | 21 |
multiple breath | 21 |
ischemic heart | 21 |
young smokers | 21 |
calcium chelators | 21 |
participants reported | 21 |
whole airway | 21 |
adult ed | 21 |
novel therapies | 21 |
new bpd | 21 |
arterial oxygen | 21 |
weeks gestation | 21 |
specific ige | 21 |
best guess | 21 |
lung inflation | 21 |
ultrafi ne | 21 |
end products | 21 |
eb vs | 21 |
disease characterized | 21 |
induced neutrophilic | 21 |
one month | 21 |
brain death | 21 |
assessment tool | 21 |
short course | 21 |
treat asthma | 21 |
new york | 21 |
low levels | 21 |
infective exacerbations | 21 |
chest ct | 21 |
stage nsclc | 21 |
increased ar | 21 |
south australia | 21 |
prospectively collected | 20 |
disease respiratory | 20 |
died within | 20 |
short term | 20 |
analysis using | 20 |
background asthma | 20 |
following acute | 20 |
month follow | 20 |
pediatric intensive | 20 |
overall prevalence | 20 |
remaining patients | 20 |
last year | 20 |
asthmatic airways | 20 |
high doses | 20 |
birth cohort | 20 |
frequently detected | 20 |
cell differentiation | 20 |
msc administration | 20 |
computerized tomography | 20 |
identified patients | 20 |
lps elastase | 20 |
fibrosis patients | 20 |
unclear whether | 20 |
new therapeutic | 20 |
stage copd | 20 |
disease states | 20 |
stranded rna | 20 |
severe pneumonia | 20 |
similar results | 20 |
methods participants | 20 |
main cause | 20 |
different lung | 20 |
bal fluid | 20 |
european respiratory | 20 |
con epoc | 20 |
patient comfort | 20 |
commercially available | 20 |
mice received | 20 |
may explain | 20 |
icu discharge | 20 |
stable asthma | 20 |
continuous positive | 20 |
training program | 20 |
clinical variables | 20 |
high incidence | 20 |
blood monocytes | 20 |
studied patients | 20 |
protective effects | 20 |
also observed | 20 |
latent adenoviral | 20 |
also used | 20 |
underlying disease | 20 |
platelet aggregation | 20 |
qualitative study | 20 |
british thoracic | 20 |
patient education | 20 |
viral etiology | 20 |
retrospectively reviewed | 20 |
among copd | 20 |
past months | 20 |
oxygen tension | 20 |
cultured airway | 20 |
human monocytes | 20 |
academic medical | 20 |
reduced levels | 20 |
may improve | 20 |
life expectancy | 20 |
exacerbations requiring | 20 |
high flow | 20 |
sensitive asthma | 20 |
failure due | 20 |
emphysema severity | 20 |
nasal cannula | 20 |
electronic medical | 20 |
human monocyte | 20 |
blood loss | 20 |
supplemental oxygen | 20 |
predictive values | 20 |
including patients | 20 |
written informed | 20 |
cardiometabolic multimorbidity | 20 |
mortality among | 20 |
higher prevalence | 20 |
high resolution | 20 |
hours later | 20 |
respiratory support | 20 |
cfu ml | 20 |
auckland city | 20 |
dyspnoea scale | 20 |
aspergillus fumigatus | 20 |
use cpap | 20 |
underwent bronchoscopy | 20 |
one third | 20 |
mast cell | 20 |
patients will | 20 |
therapeutic hypothermia | 20 |
patients included | 20 |
flow rates | 20 |
single dose | 20 |
patient days | 20 |
significant reductions | 20 |
budesonide formoterol | 20 |
airway infection | 20 |
cause mortality | 19 |
support nil | 19 |
ecm protein | 19 |
increasing frequency | 19 |
single center | 19 |
purulent sputum | 19 |
sleep studies | 19 |
steroid therapy | 19 |
alveolar lavage | 19 |
patient group | 19 |
binding protein | 19 |
using spss | 19 |
negative correlation | 19 |
surveillance data | 19 |
based study | 19 |
mucolytic agents | 19 |
venous thromboembolism | 19 |
samples taken | 19 |
derived macrophages | 19 |
including asthma | 19 |
ion transport | 19 |
eosinophil counts | 19 |
health issue | 19 |
study demonstrates | 19 |
advanced lung | 19 |
also known | 19 |
beneficial effect | 19 |
prospectively studied | 19 |
suspected infection | 19 |
disease severe | 19 |
patient died | 19 |
may benefit | 19 |
arterial ph | 19 |
investigate whether | 19 |
esophageal pressure | 19 |
copd airway | 19 |
severe exacerbation | 19 |
beneficial effects | 19 |
supine position | 19 |
health professionals | 19 |
th response | 19 |
pulse rate | 19 |
viral clearance | 19 |
significant association | 19 |
first day | 19 |
based cohort | 19 |
regression models | 19 |
within minutes | 19 |
splice variant | 19 |
asthmatic compared | 19 |
six months | 19 |
human alveolar | 19 |
neutrophil numbers | 19 |
multivariable logistic | 19 |
healthy children | 19 |
care workers | 19 |
three cases | 19 |
mean sd | 19 |
elderly asthmatic | 19 |
analysis revealed | 19 |
rehabilitation program | 19 |
surfactant proteins | 19 |
therapeutic targets | 19 |
dental treatment | 19 |
department visits | 19 |
capillary blood | 19 |
proinfl ammatory | 19 |
sleep medicine | 19 |
exacerbation rates | 19 |
healthcare professionals | 19 |
studies investigating | 19 |
cell granzyme | 19 |
exposed mice | 19 |
innate lymphoid | 19 |
care setting | 19 |
primary objective | 19 |
mean time | 19 |
early stage | 19 |
controlled study | 19 |
two cases | 19 |
major role | 19 |
tracheal intubation | 19 |
may protect | 19 |
rehabilitation programmes | 19 |
control cells | 19 |
per million | 19 |
stage i | 19 |
ipf subjects | 19 |
community hospitals | 19 |
often associated | 19 |
old smokers | 19 |
pairwise comparisons | 19 |
airway inflammatory | 19 |
reported increased | 19 |
regional hospital | 19 |
using multiple | 19 |
gestational age | 19 |
term oxygen | 19 |
bacterial pathogen | 19 |
early childhood | 19 |
treatment strategies | 19 |
primary diagnosis | 19 |
flow oxygen | 19 |
torres strait | 19 |
mean pulmonary | 19 |
airway neutrophils | 19 |
research group | 19 |
urban academic | 19 |
cell lysates | 19 |
educational program | 18 |
chronic exposure | 18 |
kidney disease | 18 |
term outcomes | 18 |
square test | 18 |
therapeutic management | 18 |
airway sections | 18 |
early morning | 18 |
fat intake | 18 |
cpap therapy | 18 |
angiotensin converting | 18 |
stable disease | 18 |
cardiac failure | 18 |
care med | 18 |
may reflect | 18 |
antiviral responses | 18 |
cantly increased | 18 |
bronchial brushings | 18 |
ecm proteins | 18 |
healthcare costs | 18 |
eosinophilic airway | 18 |
nitrogen washout | 18 |
predicted values | 18 |
body size | 18 |
pulmonary capillary | 18 |
methods consecutive | 18 |
within weeks | 18 |
care provider | 18 |
suspected pulmonary | 18 |
without affecting | 18 |
potential role | 18 |
oral antibiotics | 18 |
age yrs | 18 |
larger sample | 18 |
results indicate | 18 |
cor pulmonale | 18 |
supplementary table | 18 |
elevated levels | 18 |
human macrophages | 18 |
control cohort | 18 |
muscle mass | 18 |
correlation coefficient | 18 |
radiology department | 18 |
vena cava | 18 |
host cell | 18 |
multiple linear | 18 |
pulmonary surfactant | 18 |
average time | 18 |
cancer models | 18 |
increased apoptosis | 18 |
mineral density | 18 |
will also | 18 |
mild asthma | 18 |
reduced risk | 18 |
cultured human | 18 |
cytokine levels | 18 |
cytokine storm | 18 |
function data | 18 |
studies used | 18 |
microbiological diagnosis | 18 |
reduced airway | 18 |
large airway | 18 |
age range | 18 |
cohort studies | 18 |
macrophage activation | 18 |
several days | 18 |
ed utilization | 18 |
inflammatory effect | 18 |
causative agent | 18 |
phagocytose apoptotic | 18 |
cytokines il | 18 |
thick sections | 18 |
likert scale | 18 |
early airflow | 18 |
operating characteristic | 18 |
screening tool | 18 |
transverse airway | 18 |
niv use | 18 |
airway segments | 18 |
cells via | 18 |
program directors | 18 |
artery disease | 18 |
occurring within | 18 |
pcr assay | 18 |
copd gold | 18 |
cell cultures | 18 |
blood vessels | 18 |
exacerbation severity | 18 |
adverse outcomes | 18 |
negative bacteria | 18 |
chemokine production | 18 |
antiviral activity | 18 |
tissue disease | 18 |
clinical use | 18 |
test repetition | 18 |
treating physician | 18 |
respiratory drive | 18 |
higher rate | 18 |
pathogenic bacteria | 18 |
functional status | 18 |
enteral feeding | 18 |
showed significant | 18 |
fi beroptic | 18 |
gender differences | 18 |
bacterial culture | 18 |
pneumoniae infection | 18 |
arrest patients | 18 |
defi nition | 18 |
group received | 18 |
patient management | 18 |
patients managed | 18 |
refractory asthma | 18 |
international guidelines | 18 |
surgical patients | 18 |
healthy non | 18 |
severity scores | 18 |
matrix metalloproteinases | 18 |
lymphoid cells | 18 |
cell subsets | 18 |
consecutive days | 18 |
alcohol consumption | 18 |
clinical manifestations | 18 |
random sample | 18 |
ace expression | 18 |
routine use | 18 |
airway surface | 18 |
major source | 18 |
chest physicians | 18 |
patients experiencing | 18 |
nosocomial infections | 18 |
primary pulmonary | 18 |
care patients | 18 |
refl ect | 18 |
situ hybridization | 18 |
regression analyses | 18 |
lung epithelium | 18 |
acute effects | 18 |
birth weight | 18 |
chi squared | 18 |
obese patients | 18 |
myeloid cells | 18 |
profi les | 18 |
strong positive | 18 |
dna sequencing | 18 |
service providers | 18 |
prospectively followed | 18 |
contact tracing | 18 |
copd groups | 18 |
fev decline | 18 |
moderate copd | 18 |
oesophageal reflux | 18 |
common condition | 17 |
mechanisms involved | 17 |
also contribute | 17 |
ethics approval | 17 |
infections due | 17 |
onset asthma | 17 |
prognostic value | 17 |
nasal samples | 17 |
first episode | 17 |
requiring hospital | 17 |
cells obtained | 17 |
adult lung | 17 |
mature dcs | 17 |
high altitude | 17 |
major contributor | 17 |
steady state | 17 |
small sample | 17 |
inflammatory disease | 17 |
outcome variable | 17 |
cell transplantation | 17 |
copd management | 17 |
transcriptional regulation | 17 |
recognition molecules | 17 |
term effects | 17 |
study also | 17 |
asthma prevalence | 17 |
requiring hospitalisation | 17 |
also collected | 17 |
procedures performed | 17 |
relatively low | 17 |
practice guidelines | 17 |
ischemic stroke | 17 |
haemophilus infl | 17 |
comorbid conditions | 17 |
middle east | 17 |
obstructive airways | 17 |
life support | 17 |
least days | 17 |
young ipf | 17 |
infection studies | 17 |
different types | 17 |
based therapies | 17 |
dence interval | 17 |
randomized study | 17 |
gene therapy | 17 |
seven days | 17 |
antimicrobial activity | 17 |
subgroup analyses | 17 |
gas flow | 17 |
matched control | 17 |
baseline data | 17 |
mean bmi | 17 |
progressive dyspnoea | 17 |
extracorporeal membrane | 17 |
visual analogue | 17 |
data sets | 17 |
commercial aircraft | 17 |
disease process | 17 |
three times | 17 |
metered dose | 17 |
membrane oxygenation | 17 |
patients also | 17 |
qualitative analysis | 17 |
important roles | 17 |
functional residual | 17 |
following parameters | 17 |
uenza infection | 17 |
risk assessment | 17 |
lung lobes | 17 |
general hospital | 17 |
assisted ventilation | 17 |
basement membrane | 17 |
confi dence | 17 |
standard therapy | 17 |
collected using | 17 |
months following | 17 |
virus load | 17 |
mrna levels | 17 |
ed users | 17 |
care professionals | 17 |
crucial role | 17 |
severe complications | 17 |
bronchial mucosa | 17 |
chronic pulmonary | 17 |
statistically different | 17 |
cases per | 17 |
antimicrobial peptide | 17 |
clinical problems | 17 |
outcomes included | 17 |
early treatment | 17 |
pulmonary involvement | 17 |
novel therapeutic | 17 |
cytokine il | 17 |
white blood | 17 |
organ donation | 17 |
baseline fev | 17 |
blood glucose | 17 |
sputum eosinophilia | 17 |
task force | 17 |
point scale | 17 |
days later | 17 |
co removal | 17 |
cell entry | 17 |
care utilization | 17 |
clinically diagnosed | 17 |
inflammatory airway | 17 |
copd population | 17 |
microbial colonization | 17 |
smear positive | 17 |
gastrointestinal tract | 17 |
low rate | 17 |
attending physicians | 17 |
admission rate | 17 |
mg day | 17 |
tlr expression | 17 |
function parameters | 17 |
cerebral blood | 17 |
general practitioner | 17 |
provides additional | 17 |
residual capacity | 17 |
antibiotic administration | 17 |
categorical variables | 17 |
increased il | 17 |
also significantly | 17 |
therapy may | 17 |
also signifi | 17 |
protected specimen | 17 |
risk groups | 17 |
negative result | 17 |
qualitative research | 17 |
allergic inflammation | 17 |
severity index | 17 |
confounding factors | 17 |
fold higher | 17 |
france correspondence | 17 |
hrv infection | 17 |
systemic vascular | 17 |
clinical relevance | 17 |
prior studies | 17 |
i min | 17 |
included age | 17 |
induced copd | 17 |
tumor suppressor | 17 |
ndings suggest | 17 |
remains high | 17 |
receive either | 17 |
included studies | 17 |
nasopharyngeal aspirates | 17 |
tested positive | 17 |
gold criteria | 17 |
host defence | 17 |
without diabetes | 17 |
lung elastic | 17 |
cell senescence | 17 |
daily life | 17 |
en charge | 17 |
post treatment | 17 |
lower lung | 17 |
different levels | 17 |
human peripheral | 17 |
participants will | 17 |
alternative splicing | 17 |
will focus | 17 |
national institutes | 16 |
fl uenza | 16 |
cell number | 16 |
fi cient | 16 |
systemic levels | 16 |
required mechanical | 16 |
enclosure volume | 16 |
care medicine | 16 |
ground glass | 16 |
prevalence rates | 16 |
fat meal | 16 |
respiratory ward | 16 |
different clinical | 16 |
human studies | 16 |
tof depth | 16 |
median duration | 16 |
immunosuppressed patients | 16 |
internal control | 16 |
immune function | 16 |
neutropenic patients | 16 |
glutathione peroxidase | 16 |
immune evasion | 16 |
structural changes | 16 |
patient populations | 16 |
uncommon cause | 16 |
mean length | 16 |
acute bacterial | 16 |
congenital heart | 16 |
clinically stable | 16 |
baseline measurements | 16 |
airway compliance | 16 |
currently available | 16 |
preschool children | 16 |
study performed | 16 |
following exposure | 16 |
per week | 16 |
census tracts | 16 |
discharged patients | 16 |
ipratropium bromide | 16 |
team functionality | 16 |
two decades | 16 |
pulmonary delivery | 16 |
degrading enzymes | 16 |
cognitive impairment | 16 |
fl ammatory | 16 |
research project | 16 |
cant reduction | 16 |
direct effect | 16 |
mean dose | 16 |
online learning | 16 |
cardiopulmonary bypass | 16 |
previous research | 16 |
among people | 16 |
airway eosinophilia | 16 |
early intervention | 16 |
sampling method | 16 |
dead space | 16 |
presenting cells | 16 |
increased neutrophil | 16 |
sd age | 16 |
mdi spacer | 16 |
closely related | 16 |
gene silencing | 16 |
vlcd program | 16 |
significantly correlated | 16 |
fiberoptic bronchoscopy | 16 |
copd care | 16 |
normal values | 16 |
allergic airways | 16 |
prostate cancer | 16 |
home oxygen | 16 |
adult population | 16 |
collected information | 16 |
aecopd patients | 16 |
equally effective | 16 |
tumour necrosis | 16 |
electronic health | 16 |
los pacientes | 16 |
clinical suspicion | 16 |
respiratory comorbidity | 16 |
mandibular enclosure | 16 |
bosentan therapy | 16 |
increased release | 16 |
critical illness | 16 |
also reported | 16 |
multiple logistic | 16 |
may include | 16 |
ii receptor | 16 |
remain poorly | 16 |
disease associated | 16 |
head trauma | 16 |
airway mucus | 16 |
executive summary | 16 |
endothelial cell | 16 |
data showed | 16 |
study found | 16 |
mouse lung | 16 |
human mesenchymal | 16 |
dose inhaler | 16 |
western blotting | 16 |
research council | 16 |
critical actions | 16 |
dry cough | 16 |
medical icu | 16 |
reported asthma | 16 |
tlr activation | 16 |
pain scores | 16 |
acute coronary | 16 |
two hours | 16 |
western australia | 16 |
health workers | 16 |
negative exacerbations | 16 |
lockdown periods | 16 |
clinical evidence | 16 |
experimental studies | 16 |
day following | 16 |
jugular vein | 16 |
unknown etiology | 16 |
multiple records | 16 |
mrna stability | 16 |
aqol scores | 16 |
dysfunction may | 16 |
complications occurred | 16 |
positive biopsy | 16 |
first two | 16 |
competing interests | 16 |
case review | 16 |
health service | 16 |
functional capacity | 16 |
emergency physician | 16 |
cochrane review | 16 |
respirology doi | 16 |
frequent ed | 16 |
time periods | 16 |
copd treatment | 16 |
early adulthood | 16 |
signed ranks | 16 |
blood vessel | 16 |
become available | 16 |
drug resistance | 16 |
medical ward | 16 |
hrv infections | 16 |
severe cases | 16 |
first strategy | 16 |
diseases including | 16 |
including il | 16 |
medical thoracoscopy | 16 |
higher among | 16 |
impaired lung | 16 |
gp dstat | 16 |
enrolled patients | 16 |
data show | 16 |
increased likelihood | 16 |
used prior | 16 |
bacterial cultures | 16 |
suffi cient | 16 |
pilot data | 16 |
normal day | 16 |
copd progression | 16 |
exacerbation events | 16 |
em residency | 16 |
every hours | 16 |
underwent lung | 16 |
tumor growth | 16 |
ova challenge | 16 |
individual patients | 16 |
will improve | 16 |
adults aged | 16 |
smokers without | 16 |
hypoxic challenge | 16 |
subgroup analysis | 16 |
continuous variables | 16 |
injection drug | 16 |
key macrophage | 16 |
volume curve | 16 |
chronic kidney | 16 |
ventilator settings | 16 |
reflux disease | 16 |
aberrant activation | 16 |
high proportion | 16 |
post infection | 16 |
mean ages | 16 |
may allow | 16 |
influenza epidemics | 16 |
therapeutic potential | 16 |
ild patients | 16 |
disease role | 16 |
outpatient clinic | 16 |
months prior | 16 |
signi fi | 16 |
evaluate whether | 16 |
hospitalization due | 16 |
center study | 16 |
increased use | 16 |
cellular proliferation | 16 |
study protocol | 16 |
using polymerase | 16 |
malignant pleural | 16 |
drug development | 16 |
central nervous | 16 |
ems system | 16 |
respiratory society | 16 |
primary cells | 16 |
using immunohistochemistry | 16 |
mainly due | 16 |
survival rates | 16 |
cantly improved | 16 |
routine clinical | 16 |
one patients | 16 |
first line | 16 |
fourth leading | 16 |
fi breoptic | 16 |
using single | 16 |
refl ex | 16 |
ros production | 16 |
human health | 16 |
phagocytic function | 16 |
disease acute | 15 |
older asthmatic | 15 |
data suggests | 15 |
thoracic physicians | 15 |
three days | 15 |
mesenchymal markers | 15 |
clinical evaluation | 15 |
specimens obtained | 15 |
healthy control | 15 |
lipid peroxidation | 15 |
skin test | 15 |
brosis bronchiectasis | 15 |
later age | 15 |
east respiratory | 15 |
acting bronchodilators | 15 |
patients seen | 15 |
chemokine receptor | 15 |
tissue damping | 15 |
per cent | 15 |
readmission rates | 15 |
roc curve | 15 |
contributing factor | 15 |
management algorithm | 15 |
protein level | 15 |
cost per | 15 |
virus type | 15 |
medical therapy | 15 |
increased ace | 15 |
might also | 15 |